Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Sells $45,300.00 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder James Peyer sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $9.06, for a total transaction of $45,300.00. Following the completion of the transaction, the insider owned 177,654 shares in the company, valued at approximately $1,609,545.24. This trade represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

James Peyer also recently made the following trade(s):

• On Monday, December 8th, James Peyer sold 3,105 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $8.59, for a total transaction of $26,671.95.
• On Tuesday, December 9th, James Peyer sold 3,507 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $7.96, for a total transaction of $27,915.72.
• On Friday, December 5th, James Peyer sold 16,295 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $11.50, for a total transaction of $187,392.50.

Sensei Biotherapeutics Stock Performance

NASDAQ SNSE opened at $8.57 on Thursday. Sensei Biotherapeutics, Inc. has a 52-week low of $5.00 and a 52-week high of $18.35. The company has a fifty day moving average of $9.83 and a 200-day moving average of $8.63. The company has a market capitalization of $10.81 million, a P/E ratio of -0.45 and a beta of 0.32.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings results on Friday, November 14th. The company reported ($3.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.11) by $0.49. As a group, analysts forecast that Sensei Biotherapeutics, Inc. will post -1.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on SNSE. HC Wainwright downgraded Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sensei Biotherapeutics in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $55.00.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.